BGI Genomics Co., Ltd.

BGI Genomics Co., Ltd. saw a daily increase on June 29, 2026, despite facing significant long-term challenges, including a 26.99% decline over the past year. The company has reported declining net sales and negative operating profit growth, with a market capitalization of CNY 14,608 million.

BGI Genomics Co., Ltd. saw a significant intraday increase on June 18, 2026, contrasting with a decline in the China Shanghai Composite. Despite recent gains, the company has struggled over the past year and three years, with notable declines in net sales and operating profit, alongside a high debt-equity ratio.

BGI Genomics Co., Ltd. faced a decline in stock price, dropping 3.78% on May 22, 2026. The company has experienced significant decreases over the past week and month, with long-term performance showing a year-to-date decline of 17.48% and a 68.63% drop over five years, amid broader market contrasts.

BGI Genomics Co., Ltd. has faced significant stock volatility, with a notable decline in its performance over various timeframes. The company has struggled with negative financial results for 16 consecutive quarters, alongside concerning metrics such as a negative operating cash flow and a low return on equity, indicating ongoing challenges.

BGI Genomics Co., Ltd. faced a significant stock decline, reflecting ongoing financial challenges. The company has experienced a notable decrease in stock performance over various timeframes, including a substantial annual drop. Financial metrics indicate persistent difficulties, with negative operating cash flow and a prolonged period of unprofitability.

BGI Genomics Co., Ltd. faced a notable stock decline on March 3, 2026, amid ongoing challenges, including 16 consecutive quarters of negative results and a significant drop in operating profit over five years. The company's market capitalization stands at CNY 20,164 million as it navigates a tough sector.